This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liu, Z.-J. Articles by Zhu, B. T. Search for Related Content PubMed PubMed Citation Articles by Liu, Z.-J. Articles by Zhu, B. T.

Selective Insensitivity of ZR-75-1 Human Breast Cancer Cells to 2-Methoxyestradiol: Evidence for Type II 17ß-Hydroxysteroid Dehydrogenase as the Underlying Cause

Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina

Requests for reprints: Bao Ting Zhu, Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of South Carolina, Room 617, Coker Life Sciences Building, 700 Sumter Street, Columbia, SC 29208. Phone: 803-777-4802; Fax: 803-777-8356; E-mail: btzhu{at}cop.sc.edu.

2-Methoxyestradiol (2-MeO-E₂), a nonpolar endogenous metabolite of 17ß-estradiol, has strong antiproliferative, apoptotic, and antiangiogenic actions. Among the four human breast cancer cell lines tested (MCF-7, T-47D, ZR-75-1, and MDA-MB-435s), the ZR-75-1 cells were selectively insensitive to the antiproliferative actions of 2-MeO-E₂, although these cells had a similar sensitivity as other cell lines to several other anticancer agents (5-fluorouracil, mitomycin C, doxorubicin, colchicine, vinorelbine, and paclitaxel). Mechanistically, this insensitivity is largely attributable to the presence of high levels of a steroid-selective metabolizing enzyme, the type II 17ß-hydroxysteroid dehydrogenase (17ß-HSD), in the ZR-75-1 cells, which rapidly converts 2-MeO-E₂ to the inactive 2-methoxyestrone, but this enzyme does not metabolically inactivate other nonsteroidal anticancer agents. The type II 17ß-HSD–mediated conversion of 2-MeO-E₂ to 2-methoxyestrone in ZR-75-1 cells followed the first-order kinetics, with a very short half-life (2 hours). In comparison, the T-47D, MCF-7, and MDA-MB-435s human breast cancer cells, which were highly sensitive to 2-MeO-E₂, had very low or undetectable catalytic activity for the conversion of 2-MeO-E₂ to 2-methoxyestrone. Reverse transcription-PCR analysis of the mRNA levels of three known oxidative 17ß-HSD isozymes (types II, IV, and VIII) revealed that only the type II isozyme was selectively expressed in the ZR-75-1 cells, whereas the other two isozymes were expressed in all four cell lines. Taken together, our results showed, for the first time, that the high levels of type II 17ß-HSD present in ZR-75-1 cells were largely responsible for the facile conversion of 2-MeO-E₂ to 2-methoxyestrone and also for the selective insensitivity to the antiproliferative actions of 2-MeO-E₂.

This article has been cited by other articles:

				S. Kato, A. Sadarangani, S. Lange, M. Villalon, J. Branes, J. J Brosens, G. I Owen, and M. Cuello The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium Endocr. Relat. Cancer, June 1, 2007; 14(2): 351 - 368. [Abstract] [Full Text] [PDF]

				A Jansson, C Gunnarsson, and O Stal Proliferative responses to altered 17{beta}-hydroxysteroid dehydrogenase (17HSD) type 2 expression in human breast cancer cells are dependent on endogenous expression of 17HSD type 1 and the oestradiol receptors. Endocr. Relat. Cancer, September 1, 2006; 13(3): 875 - 884. [Abstract] [Full Text] [PDF]